23:44 , May 10, 2017 |  BC Extra  |  Company News

Management tracks

RNA company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced several additions. The biotech named Alan Eisenberg VP of global public policy and government relations; Theresa Heggie SVP and head of Europe and Canada; Peter Smith SVP of...
23:59 , Jan 10, 2017 |  BC Extra  |  Clinical News

Paper suggests Aravive compound could block Zika

In a study published Tuesday in Cell Reports , researchers from INSERM and Aravive Biologics Inc. (Houston, Texas) said Aravive’s preclinical candidate Aravive-S6 could protect glial cells from Zika infection. Aravive-S6 is an Fc-fusion protein...
19:41 , Dec 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML); breast cancer; ovarian cancer Cell culture and mouse studies suggest a GAS6 -binding AXL decoy could help treat AML and metastatic breast and ovarian cancers. The AXL decoy, Aravive-S6 ,...
20:46 , Dec 15, 2016 |  BC Innovations  |  Targets & Mechanisms

Keeping the Gas off AXL

With its development of an AXL decoy able to trap and sequester the native receptor’s ligand with femtomolar affinity, Aravive Biologics Inc. believes it has a biologic that can bypass the potency and selectivity issues...
07:00 , Oct 30, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer AXL receptor tyrosine kinase (AXL; UFO); growth arrest-specific 6 (GAS6) In vitro and mouse studies suggest an AXL-Fc fusion protein could help prevent cancer...
07:00 , Apr 17, 2014 |  BC Innovations  |  Targets & Mechanisms

Unfolding triple-negative breast cancer

A team from Weill Cornell Medical College has found a unifying feature of triple-negative breast cancers-overactivation of the transcription factor X-box binding protein 1 -that could open the door to new therapies for this notoriously...
07:00 , Apr 18, 2013 |  BC Innovations  |  Strategy

Multiple myeloma partners

The Institute of Cancer Research and Cancer Research Technology Ltd. are collaborating with Janssen Research & Development of Johnson & Johnson to modulate the unfolded protein response in multiple myeloma. Although no particulars have been...
07:00 , Nov 1, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Endoplasmic reticulum to nucleus signaling 1 (ERN1; IRE1) An SAR study identified small molecule modulators of IRE1 that could be useful for treating...
07:00 , Oct 22, 2012 |  BioCentury  |  Emerging Company Profile

Sprint: Quick start in cancer

Sprint Bioscience AB is leveraging its founders' expertise in fragment-based drug discovery and structural biology to generate leads against novel cancer metabolism and autophagy targets. The biotech hopes to out-license its therapeutics when the molecules...
07:00 , May 21, 2012 |  BC Week In Review  |  Company News

Ruga, Selexagen Therapeutics deal

Ruga acquired a RAF program from cancer company Selexagen. The program is in preclinical testing for cancers with activation of the MAP kinase pathway, including those with BRAF mutations, with an IND submission slated for...